West Pharmaceutical Services Inc. (NYSE:WST) shares hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $82.00 and last traded at $82.00, with a volume of 113,394 shares traded. The stock had previously closed at $81.33.

WST has been the subject of several research reports. Janney Montgomery Scott restated a “buy” rating and set a $90.00 price objective (up from $69.00) on shares of West Pharmaceutical Services in a research report on Friday, May 13th. Jefferies Group lifted their price objective on West Pharmaceutical Services from $67.00 to $77.00 and gave the stock a “hold” rating in a research report on Friday, July 29th. Finally, Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $91.00 price target for the company in a report on Friday, August 5th.

The firm’s 50-day moving average is $78.02 and its 200 day moving average is $70.15. The firm has a market capitalization of $5.91 billion and a P/E ratio of 58.76.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 28th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.56 by $0.03. The firm earned $388 million during the quarter, compared to the consensus estimate of $384.58 million. West Pharmaceutical Services’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same quarter last year, the company posted $0.47 EPS. Analysts anticipate that West Pharmaceutical Services Inc. will post $2.23 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 3rd. Stockholders of record on Wednesday, July 20th were issued a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Monday, July 18th.

In other news, VP Daniel Malone sold 3,950 shares of the stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $74.95, for a total value of $296,052.50. Following the completion of the transaction, the vice president now directly owns 30,666 shares in the company, valued at $2,298,416.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas W. Hofmann sold 2,466 shares of the stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $73.57, for a total transaction of $181,423.62. Following the completion of the transaction, the director now owns 34,506 shares of the company’s stock, valued at $2,538,606.42. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of WST. RS Investment Management Co. LLC boosted its position in West Pharmaceutical Services by 7.6% in the fourth quarter. RS Investment Management Co. LLC now owns 1,921,695 shares of the company’s stock valued at $115,724,000 after buying an additional 136,400 shares during the period. Vanguard Group Inc. boosted its position in West Pharmaceutical Services by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,321,348 shares of the company’s stock valued at $320,452,000 after buying an additional 46,295 shares during the period. First Trust Advisors LP boosted its position in West Pharmaceutical Services by 104.5% in the fourth quarter. First Trust Advisors LP now owns 24,581 shares of the company’s stock valued at $1,480,000 after buying an additional 12,560 shares during the period. Principal Financial Group Inc. boosted its position in West Pharmaceutical Services by 2.8% in the fourth quarter. Principal Financial Group Inc. now owns 226,582 shares of the company’s stock valued at $13,645,000 after buying an additional 6,187 shares during the period. Finally, GSA Capital Partners LLP boosted its position in West Pharmaceutical Services by 17.9% in the fourth quarter. GSA Capital Partners LLP now owns 17,134 shares of the company’s stock valued at $1,032,000 after buying an additional 2,601 shares during the period.

West Pharmaceutical Services, Inc is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.